<DOC>
	<DOCNO>NCT00417053</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Sometimes , surgery , tumor may need treatment progress . In case , observation may sufficient . It yet know combination chemotherapy regimen give together surgery , without autologous bone marrow peripheral stem cell transplant , effective treat newly diagnose neuroblastoma . PURPOSE : This phase III trial study combination chemotherapy see regimen give together surgery , without autologous bone marrow peripheral stem cell transplant , work treat infant newly diagnose neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With Without Autologous Bone Marrow Peripheral Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine outcome , term survival morbidity , infant localize , unresectable , non-MYCN-amplified neuroblastoma treat reduced-intensity chemotherapy . - Determine survival infant stage 4S neuroblastoma , MYCN amplification , bone , CNS , pleural/lung metastasis treat short-course intensive chemotherapy . - Determine survival infant stage 4S neuroblastoma , MYCN amplification , bone , CNS , pleural/lung metastasis treat intensive high-dose chemotherapy consolidation . - Determine survival infant stage ( except stage 1 ) neuroblastoma MYCN amplification treat intensive consolidation high-dose chemotherapy follow autologous bone marrow stem cell support . Secondary - Correlate outcome factor stage MYCN status infant neuroblastoma . - Define behavior neuroblastoma infant treat regimen . - Determine prognostic criterion infant treat regimen . - Determine whether deletion chromosome 1p diploidy/tetraploidy prognostic factor infant adverse feature , MYCN amplification . OUTLINE : This nonrandomized , multicenter study . Patients assign 1 4 treatment regimen accord disease criterion . Patients eligible regimen ( stage 1 resectable stage 2 disease ) undergo surgical resection follow observation . - Regimen NB 99.1 ( unresectable stage 2 3 ) : Patients treat accord spinal cord involvement presence neurological symptom . - Group I ( evidence spinal cord involvement ) : - CO therapy : Patients receive cyclophosphamide IV day 1-5 vincristine IV day 1 . Treatment repeat every 14 day 4 course absence disease progression . Resectability assess every 2 course chemotherapy ; tumor resectable , patient undergo surgery follow observation . If , 4 course CO , tumor still resectable disease progress , patient proceed VP-CARBO therapy . - VP-CARBO therapy : Patients receive carboplatin IV 1 hour etoposide phosphate IV 2 hour day 1-3 . Treatment repeat every 21 day 2 course . If tumor deem resectable , patient undergoes surgery . If tumor resectable disease progress , patient proceed CADO therapy . - CADO therapy : Patients receive cyclophosphamide IV 1 hour day 1-5 , doxorubicin hydrochloride IV 6 hour day 4 5 , vincristine IV day 1 5 . Treatment repeat every 21 day 2 course . Patients proceed resection biopsy . - Group II ( dumbbell tumor , spinal cord compression symptom life-threatening symptom [ e.g. , respiratory obstruction ] ) : Patients receive 2 course VP-CARBO therapy . Patients achieve response proceed surgery biopsy extraspinal portion resectable . Patients nonresponding disease unresectable extraspinal portion tumor receive 2 course CADO therapy undergo surgery biopsy . Patients dumbbell tumor spinal cord compression symptom treat group I . - Regimen NB 99.2 ( stage 4S stage 4 without bone , pleura/lung , CNS metastases MYCN amplification ) : Patients severe life-threatening symptom observe spontaneous regression disease . Patients severe symptom receive 1 course VP-CARBO therapy . Patients Philadelphia score ≥ 2 ( ≥ 1 neonate [ &lt; 1 month old ] ) receive second course VP-CARBO therapy . If disease respond 2 course VP-CARBO therapy , patient receive 4 course CADO therapy . Treatment cease response obtain . Surgery allow require . - Regimen NB 99.3 ( skeletal bone , pleural , and/or CNS metastasis , MYCN amplification ) : Patients receive 2 course VP-CARBO therapy . Patients respond disease receive 2 course proceed surgery ( possible ) . Patients disease progression response first 2 course VP-CARBO therapy patient experience metastatic complete response ( CR ) 4 course VP-CARBO therapy receive 4 course CADO therapy . Patients proceed surgery , possible , 2-4 course CADO therapy . - Regimen NB 99.4 ( stage 2-4 disease MYCN amplification ) : Patients receive 2 course VP-CARBO therapy follow 2 course CADO therapy surgery ( already perform ) . Patients receive filgrastim ( G-CSF ) subcutaneously 5 day second course CADO therapy surgery . Patients also undergo collection bone marrow peripheral blood stem cell ( PBSC ) . Patients undergo surgery receive 1 course VP-CARBO therapy follow 1 course CADO therapy postsurgery . At least 3 week third course CADO therapy , patient receive high-dose chemotherapy comprise busulfan every 6 hour day -7 -3 melphalan IV day -2 follow autologous bone marrow PBSC infusion day 0 . At least 2 month later , patient undergo radiotherapy primary tumor site , even complete surgical resection accomplish . Patients stage 4 disease achieve metastatic CR chemotherapy ( surgery ) go study . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 330 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm neuroblastoma ganglioblastoma Newly diagnose disease MYCN status know Patients assign different study treatment regimens* accord follow disease criterion : Regimen NB 99.1 Localized unresectable tumor If open surgery consider hazardous due site tumor condition infant , cytological confirmation allow , provide adequate material obtain study procedures No MYCN amplification ( i.e. , &lt; 10 copy ) No metastatic deposit bone marrow No MIBG technetium uptake radiological bone lesion skeleton No liver disease ultrasound Regimen NB 99.2 Stage 4 4S metastasis confine skin , marrow , node , liver No bone involvement radiographs No pleural lung involvement No CNS involvement No MYCN amplification ( i.e. , &lt; 10 copy ) Regimen NB 99.3 Stage 4 disease , metastases must meet ≥ 1 follow criterion : Skeletal bone metastases plain xray CT scan Pleural lung metastasis CNS involvement No MYCN amplification ( i.e. , &lt; 10 copy ) Regimen NB 99.4 Stage 24 disease MYCN amplification ( i.e. , ≥ 10 copy ) NOTE : *Patients stage 1 resectable stage 2 disease MYCN amplification ( i.e. , &lt; 10 copy ) eligible study treatment regimen may enrol study observation PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>